

ORIGINAL WORK



Intracerebral Proinflammatory Cytokine Increase in Surgically Evacuated Intracerebral Hemorrhage: A Microdialysis Study

Lovisa Tobieson^{1*} , Anna Gard², Karsten Ruscher² and Niklas Marklund^{2,3}

© 2021 The Author(s)

Abstract

Background: Treatment options for spontaneous intracerebral hemorrhage (ICH) are limited. A possible inflammatory response in the brain tissue surrounding an ICH may exacerbate the initial injury and could be a target for treatment of subsequent secondary brain injury. The study objective was to compare levels of inflammatory mediators in the interstitial fluid of the perihemorrhagic zone (PHZ) and in seemingly normal cortex (SNX) in the acute phase after surgical evacuation of ICH, with the hypothesis being that a difference could be demonstrated between the PHZ and the SNX.

Methods: In this observational study, ten patients needing surgical evacuation of supratentorial ICH received two cerebral microdialysis catheters: one in the PHZ and one in the SNX that is remote from the ICH. The microdialysate was analyzed for energy metabolites (including lactate pyruvate ratio and glucose) and for inflammatory mediators by using a multiplex immunoassay of 27 cytokines and chemokines at 6–10 h, 20–26 h, and 44–50 h after surgery.

Results: A metabolic crisis, indicated by altered energy metabolic markers, that persisted throughout the observation period was observed in the PHZ when compared with the SNX. Proinflammatory cytokines interleukin (IL) 8, tumor necrosis factor α , IL-2, IL-1 β , IL-6 and interferon γ , anti-inflammatory cytokine IL-13, IL-4, and vascular endothelial growth factor A were significantly higher in PHZ compared with SNX and were most prominent at 20–26 h following ICH evacuation.

Conclusions: Higher levels of both proinflammatory and anti-inflammatory cytokines in the perihemorrhagic brain tissue implies a complex role for inflammatory mediators in the secondary injury cascades following ICH surgery, suggesting a need for targeted pharmacological interventions.

Keywords: Brain injury, Cytokine, Inflammation mediators, Intracranial hemorrhage, Microdialysis, Stroke

Introduction

Spontaneous supratentorial intracerebral hemorrhage (ICH) represents the most severe form of stroke [1]. Current medical treatment options are limited, aimed at preventing ICH expansion [2, 3], and the role of surgery in improving outcome remains controversial [4–7].

The ICH causes an initial primary injury to the brain by direct tissue destruction and a possibly increased intracranial pressure (ICP). Subsequently, the blood break-down products and/or the increased ICP cause an additional secondary brain injury by initiating reactive cellular, metabolic, and neurotoxic cascades. The tissue surrounding an ICH, the perihemorrhagic zone (PHZ), shows an acute hypometabolic and hypoperfusion state [8–10], including mitochondrial dysfunction and metabolic failure [11, 12], and this region may be particularly vulnerable to secondary injury. Experimental

*Correspondence: lovisa.tobieson@regionostergotland.se

¹ Departments of Neurosurgery in Linköping and Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

Full list of author information is available at the end of the article

ICH studies demonstrate an inflammatory response that includes the rapid activation of microglia [13–16], followed by the infiltration of inflammatory cells over hours and days [17], which may cause additional tissue damage. Improved neurologic outcome is achieved by attenuating the inflammatory process in experimental ICH [18–21]; however, this has failed to translate into pharmacological treatment options for patients with ICH [22]. Early attempts to attenuate the ICH-induced inflammation by using glucocorticoid administration resulted in impaired clinical outcome [23], emphasizing the complex contribution of inflammation to outcome.

Cerebral microdialysis (MD) is a useful clinical tool used to monitor the microenvironment of the brain tissue in the neurocritical care patient [24–26]. Catheters with a larger pore size enable sampling of inflammatory mediators from the interstitial fluid of brain tissue in humans [27] and in animal models [28], and the cerebral interstitial cytokine expression has been explored in patients with subarachnoid hemorrhage (SAH) and traumatic brain injury (TBI) [27, 29–34], but not in patients with ICH. Several studies, however, have explored the plasma concentration of proinflammatory mediators such as interleukin (IL) 6 [35–38] and tumor necrosis factor (TNF) α [37, 38] in patients with ICH, indicating that inflammation plays a role in secondary brain injury following ICH.

In this study, we sampled interstitial fluid by using paired MD catheters, one in the PHZ and one in seemingly normal cortex (SNX), to investigate changes in inflammatory mediators in the acute phase after the surgical evacuation of ICH. We hypothesized a difference in cytokine and chemokine levels in the PHZ compared with those in the SNX.

Materials and Methods

Ethics

The study protocol was approved by the regional ethical committee in Linköping, Sweden (decision number 2014/236-31) and was conducted in accordance with relevant guidelines and regulations. Informed consent was obtained from the patient's closest relative.

Patients

Adults requiring acute ICH evacuation via open craniotomy at the Department of Neurosurgery, University Hospital, Linköping, Sweden in 2016–2018 were prospectively recruited to this observational cohort study. Severe coagulation disorders and a known source of bleeding, such as an aneurysm or an arteriovenous malformation, were exclusion criteria. ICP monitoring was achieved by using standard protocols adopted by our department [39]. One MD catheter (CMA-71 Brain

Catheter; M-Dialysis, Solna, Sweden) was inserted via the craniotomy into the PHZ within 1 cm of the evacuated ICH, and the other catheter was inserted in the SNX, as previously described [39]. A postoperative computed tomography (CT) scan was performed to verify MD catheter placement [40, 41]. Systemic inflammatory parameters in the blood were analyzed daily. Patients were treated according to a standardized neurocritical care protocol to avoid secondary insults [39]. Continuous electroencephalogram was initiated, when indicated, to rule out nonconvulsive seizure activity ($n=1$). Three patients were included in a previous publication from our group [39]. Patient records were investigated at 12 months to determine clinical outcome determined with the modified Rankin Scale (mRS).

Microdialysis

Microdialysis catheters with 10-mm membrane length and a molecular weight cutoff of 100 kDa (CMA-71) were perfused with 5% human albumin in a water solution (Albunorm, 50 g/l; Octapharma AB, Stockholm, Sweden), at a rate of 0.3 μ l/min using the CMA 106 perfusion pump (M-Dialysis AB) [27]. The first 2 h of sampling were discarded according to consensus praxis [26]. Samples were collected every 2 h for routine analysis of low-molecular weight metabolites (glucose, lactate, pyruvate, glycerol, and glutamate) [26, 42]. The remaining sample (30 μ l/vial) was stored at -86 °C until further analysis was completed.

Analytical Methods

Metabolite Analysis

Interstitial levels of glucose, lactate, pyruvate, glycerol and glutamate in the MD samples were analyzed bedside using an ISCUS Flex analyzer (M-Dialysis AB, Solna, Sweden), as previously described in detail [39].

Multiplex Immunoassay

MD samples from three postoperative time points; early (4–10 h), intermediate (20–26 h), and late (44–50 h after surgery), were analyzed for inflammatory mediators using the Meso Scale Discovery (Rockville, MD) MULTI-SPOT Assay System V-PLEX Human Proinflammatory Panel 1, Cytokine Panel 1, and Chemokine Panel 1 (cat #K15210D). The proteins were detected by immunoassays, using electrochemiluminescent labels, providing a quantitative measure of protein concentration.

To achieve a sufficient sample volume (25 μ l), 3 MD vials were pooled, resulting in a 6-h time resolution. The pooled samples were diluted to one fifth of the original concentration. All samples were analyzed with the same protocol by blinded investigators.

Antibody Solution

V-PLEX Proinflammatory Panel 1: 67 μ l of SULFO-TAG Antihuman interferon (IFN) γ , IL-1 β , IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, and TNF- α were added to 2400 μ l of diluent.

V-PLEX Cytokine Panel 1: 67 μ l of SULFO-TAG Antihuman IL-1 α , IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF- β , and vascular endothelial growth factor A (VEGF-A) were added to 2400 μ l of diluent.

V-PLEX Chemokine Panel 1: 67 μ l of SULFO-TAG Antihuman Eotaxin, macrophage inflammatory protein (MIP) 1 β , Eotaxin-3, thymus and activation regulated chemokine, IP-10, MIP-1 α , monocyte chemoattractant protein 1, macrophage derived chemokine, and monocyte chemoattractant protein 4 were added to 2400 μ l of diluent.

Assay Protocol


After blocking with blocker H, shaking for one hour, plates were washed three times with 150 μ l phosphate buffered saline (PBS + 0.05% Tween 20; wash cycle). Sample or calibrator (25 μ l) was added and plates were sealed and incubated at room temperature with shaking for 2 h, followed by three wash cycles. Antibody solution (25 μ l) was then added to each well, followed by incubation at room temperature with shaking for two hours, and subsequently three wash cycles. Finally, 2X Read Buffer T (150 μ l) was added, and the plates were analyzed with a MESO QuickPlex SQ 120 instrument.

Statistical Analyses

Statistical analyses were performed in SIMCA 17.0.0 (Umetrics, Sweden) or in IBM SPSS 27.0 (IBM, Kista, Sweden). Data distribution was assessed using Shapiro-Wilks' normality test. Low-molecular weight metabolite data were analyzed using linear mixed model (MML) method using patient number as subject level and catheter location as fixed effect. Univariate analysis was performed using paired Wilcoxon signed-rank test for nonnormally distributed data. Values below lower limit of detection (LLOD) of the assay were substituted with the exact value given for LLOD by the manufacturer. Multivariate analysis (MVA) was performed by overviewing the data using principal component analysis (PCA) and thereafter fitting an orthogonal projection to latent structures discriminant analysis (OPLS-DA) model to the data. Critical outliers were investigated with Hotelling's T² in the PCA. Moderate outliers were investigated using distance to model X (DModX) [43]. Model validity was investigated with a cross-validated ANOVA (CV-ANOVA) and a *p* value < 0.05 considered significant. Scaling to unit variance and mean centering was employed. Variables with a $|p(\text{corr})| > 0.4$ and variable influence on projection (VIP) > 1 were considered significant [43]. Hierarchical cluster analysis was performed using Ward's method. Network analysis was performed using the STRING database.

Results

Ten patients (eight men, two women; Table 1) underwent surgery with evacuation of ICH and placement of






Fig. 2 Metabolic crisis in the PHZ. **a**, Microdialysis (MD) glucose levels were significantly lower in the perihemorrhagic zone (PHZ) when compared with those in seemingly normal cortex (SNX) ($p < 0.05$), although were consistently above critical (0.2 mmol/L) and warning levels (0.8 mmol/L) in both locations [26]. **b**, The LPR, however, was pathologically elevated in the PHZ, indicating a metabolic crisis in the brain tissue. In contrast, the SNX LPR normalized within the first hours after surgery, and thereafter remained within the normal range. **c** MD-glutamate levels decreased with time in the PHZ but were significantly higher than in the SNX ($p < 0.05$) during the initial 48 h. **d**, In addition, MD-glycerol levels were persistently higher in the PHZ when compared with the SNX ($p < 0.05$). Data are presented as mean and standard error of the mean (SEM) for clarity. LPR= lactate pyruvate ratio

dual MD catheters (Fig. 1a, b). None of these patients had intraventricular hemorrhage, and an external ventricular drain (EVD) was not inserted. ICP monitoring was initiated in three patients using a parenchymal ICP monitor. Median age was 64 (51–71) years; median time to surgery from ICH onset was 27.8 (6–82) hours and median MD-sampling time was 95 (50–148) h. Mean distance from MD catheter to evacuated ICH was 6 (± 5.0) mm for the PHZ catheter and 24.5 (± 7.6) mm for the SNX catheter. Mean volume of ICH was 77 (± 25.8) ml (Table 1). The PHZ catheter of patient 10 was not placed according to protocol (> 10 mm from ICH), however, on CT control, it was located in tissue affected by the ICH and was included in the analysis. The SNX catheter of patient 7 was placed in tissue which subsequently developed an ischemic infarction thus not representing normal cortex, and the data from this MD catheter was excluded from further analysis.

White blood cell count was 9.6 (± 1.9), 10.1 (± 1.6), and 9.2 (± 2.5) $\times 10^9$ at 6–10 h, 20–26 h, and 40–46 h, respectively. C-reactive protein was 25.7 (± 28), 99.3 (± 72) and 131.4 (± 78) mg/l at 6–10 h, 20–26 h and 40–46 h, respectively. Functional outcome at 12-month follow-up is presented in Table 1.

Metabolites

MD-glucose levels were significantly lower in PHZ compared with SNX (Fig. 2a; $p < 0.05$), however, consistently above the 0.2 mmol/l critical level [26] in both locations, suggesting adequate substrate delivery. Nevertheless, the lactate-pyruvate ratio (LPR) was significantly higher in PHZ than in SNX (Fig. 2b; $p < 0.05$), indicative of a metabolic crisis in the PHZ [39], and was particularly evident early following surgery but persisting beyond 48 h. MD-glutamate and MD-glycerol

levels were also significantly higher in PHZ than in SNX (Fig. 2c, d; $p < 0.05$).

Cytokines and Chemokines

All inflammatory mediators were in detection range although their expression was highly variable with a four-fold dynamic range. TNF- β was recovered in <2% of the samples and was excluded from analysis. In total, 1,512 multiplex analysis results were obtained.

Univariate Analysis

Univariate analysis of cytokines and chemokines revealed a significantly higher level of IL-2, IL-8, and IL-1 α at 20–26 h post surgery, whereas IL-6 and IL-4 levels were increased at 44–50 h in the PHZ when compared with the SNX (Fig. 3; $p < 0.05$). Several cytokines, including most anti-inflammatory, displayed a similar pattern in the PHZ and the SNX (see Supplemental digital content Fig. 1). Chemokines had, in general, lower levels in the PHZ than in the SNX; however, only thymus and activation regulated chemokine levels were statistically different (see Supplemental digital content Fig. 2).

Multivariate Analysis

Principal component analysis illustrated clustering in the data (Fig. 4a). Hotelling's T² analysis showed two critical outliers (>99% T²) which were subsequently removed, without altering neither global nor pair wise test results. Score scatter plot for PCA showed inherent group separation in the data (Fig. 4a). The corresponding loading scatter plot showed PHZ data clustering largely due to metabolites and proinflammatory cytokines (Fig. 4b). The proinflammatory and metabolite variables clustered near time point 2 (20–26 h post surgery) as opposed to time points 1 and 3 (4–10 and 46–50 h post surgery, respectively).

A supervised OPLS-DA model was then fitted (OPLS-DA [1+0+0] $R^2=0.179$, $Q^2=0.23$; p (CV-ANOVA) <0.001) with MD catheter location as class (Fig. 4c). Four metabolites and eight cytokines showed the strongest contribution to the difference between the PHZ and SNX ($|p(\text{corr})| > 0.4$ and $\text{VIP} > 1$; Fig. 4e, Table 2). Notably, low-molecular weight metabolites

suggestive of a metabolic crisis and tissue injury such as lactate, LPR, pyruvate and glutamate, were significantly higher in PHZ when compared to the SNX. Furthermore, the proinflammatory cytokines TNF- α , IL-6, IFN- γ , IL-1 β , IL-8, and IL-2 were higher in PHZ compared to SNX, as were the anti-inflammatory cytokines IL-13 and IL-4, and growth factor VEGF-A. A hierarchical cluster analysis dendrogram of the OPLS-DA data demonstrated that inflammatory mediators and metabolites clustered into two major groups (Fig. 5a). Network analysis showed highly connected inflammatory mediators (Fig. 5b).

Discussion

By placing paired microdialysis catheters, one in the perihemorrhagic zone (PHZ) of the evacuated ICH and one in noninjured seemingly normal cortex (SNX) we could demonstrate a higher expression of predominantly proinflammatory cytokines in the PHZ compared to the SNX, most evident at 20–26 h post-surgery. Proinflammatory cytokines IL-8, TNF- α , IL-2, IL-1 β , IL-6, and IFN- γ , were significantly higher in PHZ compared to SNX.

Analysis of low-molecular weight metabolites showed a persistent metabolic crisis in the perihemorrhagic tissue, consistent with our previous study [39]. The high levels of MD-glutamate in the PHZ suggests an ongoing neuronal death, and a subsequent plausible cell membrane degradation could contribute to the gradually increasing MD-glycerol levels.

Increased proinflammatory cytokine expression in perihemorrhagic tissue including expression of IL-1 β , TNF- α , and MIP-1 α has previously been observed in animal models [18, 44–47], however, there are no previous studies of cytokine expression in brain tissue of patients with ICH. Our present findings support the presence of a proinflammatory environment in the tissue surrounding an ICH and provides information on the temporal profile of the inflammatory cascades. VEGF-A, which mediates increased permeability of the blood–brain barrier [48, 49], was distinctly higher in PHZ compared with SNX, which may then potentially aggravate vasogenic edema and cause further secondary brain injury.

The inflammatory response may also have a beneficial role in ICH, orchestrated by the M2 microglial

(See figure on next page.)

Fig. 3 Univariate analysis of cytokines. Significantly higher levels of IL-2 and IL-8 were seen in the perihemorrhagic zone (PHZ) compared with seemingly normal cortex (SNX) at 20–26 h after surgery. At 44–50 h after surgery, there was a significantly higher expression of IL-4, which is considered an anti-inflammatory cytokine, and IL-6, which is considered a proinflammatory cytokine, in the PHZ compared with the SNX. Several of the cytokines contributing to group separation in the supervised OPLS-DA model (highlighted with gray background in this figure) did not reach statistically significant differences when explored using univariate statistical methods. In contrast, IL-1 α was significantly higher in PHZ at 20–26 h after surgery in univariate analysis but did not contribute to the multivariate model. Median (line) and individual values presented: * $p < 0.05$ (Wilcoxon signed-rank test). IFN= interferon, IL= interleukin, IP-10= interferon-gamma induced protein 10, LPR= lactate pyruvate ratio, MCP= monocyte chemoattractant protein, MDC= macrophage derived chemokine, MIP= macrophage inflammatory protein, OPLS-DA= orthogonal projection to latent structures discriminant analysis, TARC= thymus and activation regulated chemokine, TNF= tumor necrosis factor, VEGF-A= vascular endothelial growth factor A




Fig. 3 (See legend on previous page.)

phenotype, involved in clearing debris and tissue repair following ICH [13–16, 18–21, 50–56]. IL-13 and IL-4, increased in the PHZ in the present study, are known to be anti-inflammatory or have a modulating effect on

proinflammatory mediators [57]. IL-4 has been shown to convert M1 phenotype microglia toward an M2 phenotype [58, 59], further illustrating that tissue reaction to

ICH is complex and the balance of anti- and proinflammatory mediators may shift over time.

A previous study of patients with TBI showed the recovery of 42 cytokines from interstitial fluid, and demonstrated distinct temporal profiles in 16 of these. Similarly to the present study, TNF- α , IL-8, IL-1 β , and IL-6 were found to peak within the first two days of monitoring [32]. Although TBI and ICH may share some characteristics, they are also two distinct disease entities with unique pathophysiologies.

Cytokines can have both a dual and conflicting role. To classify them as either anti- or proinflammatory is overly simplistic, as the inflammatory mediators constitute an intricate network of paracrine and autocrine molecules with both positive and negative feedback loops [60]. Therefore, it is important to consider both the context, the timing and the target of any given cytokine in order to understand and interpret its action as either a driver or a moderator of the immune response. In particular IL-6, TGF- β and IFN- γ can be either proinflammatory or anti-inflammatory, depending on timing and target [61]. In similarity to our present study, both anti-inflammatory and proinflammatory cytokines are released simultaneously in the tissue following TBI [62, 63].

Limitations

A limitation of cerebral microdialysis is the lack of control levels, and interpretation of absolute levels must be made with caution. Our approach enables evaluation of the temporal profile of the inflammatory cascades but also a comparison with a relatively uninjured brain region, the SNX, as it is exposed, but not injured, by the surgical approach. Because the MD catheters are placed by free-hand, some variability of their placement is

inevitable. Although this variation was small and within reasonable limits (typically < 10 mm) we cannot exclude that this variability may have influenced the results. Routine CT scans were performed postoperatively in all patients when clinically indicated, however, not at the same time points as inflammatory mediators were analyzed. Furthermore, these bedside CT scans used in our neurocritical care unit were performed using thick sections. For this reason, perihemorrhagic and postsurgical edema and its potential correlation to inflammatory mediators could not be assessed.

None of the patients had convulsive seizures, nor were any nonconvulsive seizures detected using scalp electrode electroencephalogram (EEG). However, we did not have the possibility to monitor the perihemorrhagic tissue by stereotaxically inserted deep EEG electrodes. Any local seizure activity would influence tissue metabolism and homeostasis locally. This could be explored by deep, local tissue EEG monitoring in a future study.

Relative recovery [26, 64] was not determined in the present study, however, it can be assumed to be similar between the paired catheters, thus differences between these should not be affected by changes in recovery.

This study is limited by the small number of patients, explained by the highly complex setup and the fact that only 3% of all patients with ICH in Sweden undergo surgical evacuation [65], which limits the generalizability of the results.

Ethical considerations preclude the insertion of microdialysis catheters in patients who do not undergo surgical ICH evacuation, therefore control patients are not available. The surgical approach, although performed using microsurgical technique to minimize the trauma to the surrounding tissue, may have contributed to the release

(See figure on next page.)

Fig. 4 Multivariate data analysis showed separation between PHZ and SNX. **a**, Principal component analysis (PCA) score scatter plot of cytokine and metabolite data from PHZ (black squares) and SNX (white inverted triangles) show a separation between the two groups. The PHZ data points gravitate toward the upper left quadrant, whereas the SNX data points predominantly cluster toward the lower right quadrant (dashed black circles). **b** Corresponding PCA loading scatter plot shows clustering of proinflammatory cytokines (red squares) and metabolites associated with a deranged metabolic state (black stars) to the left upper quadrant corresponding to the predominant location of PHZ data (black dashed circle) in part **a**. In contrast, MD-glucose and MD-glycerol levels cluster with SNX data points, as do chemokines (blue hexagons) and anti-inflammatory cytokines (yellow triangles). Time point 2 (20–26 h after surgery; unfilled circle) correlates with higher proinflammatory cytokine expression compared with time points 1 (4–10 h after surgery) and 3 (44–50 h after surgery), respectively, apart from IL-17A, which is distinctly correlated with time point 1. **c** Score plot of OPLS-DA model (one component) showing model separation of PHZ (black columns) and SNX (white columns) data points. **d** Loading plot of OPLS-DA model showing which variables contribute strongest (gray bars) to group separation within the model, with 95% confidence interval (error bars). **e** Volcano plot for the OPLS-DA model shows variables more specific to PHZ to the left on the x-axis and those associated with SNX to the right. Variables that contribute the strongest to group discrimination (i.e., with a $|p(\text{corr})| > 0.4$ and $\text{VIP} > 1$) are placed within the red circles. Lactate, pyruvate, LPR, and glutamate (black); proinflammatory cytokines IL-8, TNF- α , IL-2, IL-1 β , IL-6, and IFN- γ (red); anti-inflammatory cytokines IL-13 and IL-4 (yellow); and growth factor VEGF-A (blue) were higher in PHZ compared with SNX. The majority of the anti-inflammatory cytokines and chemokines did not contribute significantly to the model, suggesting that their concentrations were similar in the PHZ and the SNX. **f** S-plot indicating strength of contribution of each variable to the OPLS-DA model. GF= growth factor, IFN= interferon, IL= interleukin, IP-10= interferon-gamma induced protein 10, LPR= lactate pyruvate ratio, MCP= monocyte chemoattractant protein, MDC= macrophage derived chemokine, MIP= macrophage inflammatory protein, OPLS-DA= orthogonal projection to latent structures discriminant analysis, PHZ= perihemorrhagic zone, SNX= seemingly normal cortex, TARC= thymus and activation regulated chemokine, TNF= tumor necrosis factor, VEGF-A= vascular endothelial growth factor A, VIP = variable influence on projection.




Fig. 4 (See legend on previous page.)

Table 1 Patient characteristics

| Patient # | Sex | Age (yrs) | Time to surgery (h) | Sampling time (h) | Dist-PHZ (mm) | Dist-SNX (mm) | Volume (mL) | ICH side | ICH location | Outcome (mRS) |
|-----------|-----|-----------|---------------------|-------------------|---------------|---------------|-------------|----------|--------------|---------------|
| 1 | M | 51 | 10 | 112 | 0 | 27 | 89 | L | BG | LTF |
| 2 | M | 71 | 14 | 74 | 6 | 38 | 93 | R | LO | 2 |
| 3 | M | 64 | 82 | 148 | 6 | 20 | 43 | R | BG | 4 |
| 4 | F | 70 | 6 | 58 | 4 | 22 | 89 | L | LO | 2 |
| 5 | M | 68 | 6 | 130 | 2 | 34 | 114 | R | BG | 4 |
| 6 | M | 64 | 6 | 86 | 8 | 30 | 45 | L | BG | 1 |
| 7 | M | 63 | 58 | 146 | 9 | 11 | 44 | L | BG | 3 |
| 8 | M | 69 | 20 | 50 | 6 | 19 | 78 | R | LO | 6 |
| 9 | F | 64 | 12 | 90 | 0 | 27 | 33 | L | BG | 2 |
| 10 | M | 57 | 64 | 56 | 18 | 19 | 76 | L | BG | 3 |

BG = basal ganglia; Dist-PHZ = distance from PHZ catheter to ICH; Dist-SNX = distance from SNX catheter to ICH; F = female; h = hours; ICH = intracerebral hemorrhage; L = left; LO = lobar; LTF = lost to follow up; M = male; mRS = modified Rankin Scale; Patient # = patient number; R = right; yrs = years

Table 2 Variables contributing strongly to OPLS-DA model discriminating between PHZ and SNX

| Variable | $ p(\text{corr}) $ | VIP |
|---------------|--------------------|---------|
| Lactate | −0.77687 | 1.82257 |
| IL-13 | −0.70948 | 1.66652 |
| IL-8 | −0.6973 | 1.63755 |
| Glutamate | −0.68288 | 1.61133 |
| TNF- α | −0.66947 | 1.57238 |
| IL-2 | −0.66011 | 1.55044 |
| LPR | −0.65954 | 1.52502 |
| VEGF-A | −0.63103 | 1.48236 |
| IL-4 | −0.58531 | 1.37511 |
| IL-1 β | −0.55034 | 1.29242 |
| IL-6 | −0.54935 | 1.29079 |
| IFN- γ | −0.50683 | 1.19044 |
| Pyruvate | −0.46304 | 1.07022 |


VIP > 1 and absolute $p(\text{corr}) > 0.4$ are used to determine which variables are most important for the model, [43] meaning these variables contribute most to model group separation

IFN = interferon, IL = interleukin, LPR = lactate-pyruvate ratio, OPLS-DA = orthogonal projection to latent structures discriminant analysis, PHZ = perihemorrhagic zone, SNX = seemingly normal cortex, TNF = tumor necrosis factor, VEGF-A = vascular endothelial growth factor A, VIP = variable influence on projection

of inflammatory mediators. However, the distinct differences between the two catheters argues against a marked tissue reaction and cytokine release from insertion of the microdialysis catheter per se.

The study design precludes the discovery of cytokine peaks later than 50 h post surgery, as has previously been demonstrated for IL-12p70 and IL-10 in patients with TBI [32]. Furthermore, any peak prior to MD insertion would also evade detection. In addition, the variable time to surgery from ICH onset may have introduced uncontrolled data variability, as the ICH-induced inflammatory response likely was in different stages when surgery was performed and when MD-sampling was initiated. Nevertheless, our results show that the most significant changes occurred already at 20–26 h after surgery suggesting an early inflammatory peak following ICH.

In this present study the OPLS-DA model was employed to discern overall correlations and differences in the data. A highly significant model was developed, but the R^2 and Q^2 point to a rather large amount of noise in the data. The small sample size also precludes having separate training sets and validation data sets for the multivariate models. The model is robust enough for exploratory analysis of overall correlation patterns in the data. Further studies are required to verify the findings in this present study.



Conclusions

In this study, we compared levels of inflammatory mediators in the interstitial fluid of the PHZ with that of the CNX following surgical evacuation of ICH. We found an increased expression of proinflammatory cytokines in the PHZ 20–26 h after surgery. This acute inflammatory response may constitute a target for future therapies aiming to reduce secondary brain injury.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1007/s12028-021-01389-9>.

Author details

¹ Departments of Neurosurgery in Linköping and Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. ² Department of Clinical Sciences Lund, Neurosurgery, Lund University, Lund, Sweden. ³ Department of Clinical Sciences Lund, Neurosurgery, Lund University, Skåne University Hospital, Lund, Sweden.

Acknowledgements

The authors wish to thank the patients who were included in the study, and their relatives. The authors also thank Dr Peter Siesjö for valuable opinions on the manuscript, and Dr Emanuel Bäckryd for advice on the multivariate statistical analysis. This study was conducted using professional biobank services from Linköping Biobank Facility and Biobank Sweden, financed by the Swedish Research Council.

Author contributions

LT and NM devised the study and drafted the article. AG and KR performed the analysis of inflammatory mediators. All authors revised and edited the final article. All authors have approved the final version of the manuscript.

Source of support

Open access funding provided by Linköping University. This study was supported by grants from the Swedish State Support of Clinical Research (#ALFLio-925101) and STROKE-Riksförbundet.

Declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval/informed consent

The study protocol was approved by the regional ethical committee in Linköping, Sweden (decision number 2014/236-31) and conducted in accordance with relevant guidelines and regulations.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 9 June 2021 Accepted: 25 October 2021

Published: 30 November 2021

References

- Feigin VL, Norrving B, Mensah GA. Global burden of stroke. *Circ Res*. 2017;120:439–48.
- Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals From the American Heart Association/American Stroke Association. *Stroke J Cereb Circ*. 2015;46:2032–60.

3. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. *Int J Stroke Off J Int Stroke Soc.* 2014;9:840–55.
4. Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. *Lancet.* 2013;382:397–408.
5. Prasad K, Mendelow AD, Gregson B. Surgery for primary supratentorial intracerebral haemorrhage. *Cochrane Database Syst Rev.* 2008; Cd000200.
6. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. *Lancet.* 2005;365:387–97.
7. Sondag L, Schreuder F, Boogaarts HD, et al. Neurosurgical intervention for supratentorial intracerebral hemorrhage. *Ann Neurol.* 2020;88:239–50.
8. Qureshi AI, Palesch YY, Martin R, et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. *Arch Neurol.* 2010;67:570–6.
9. Qureshi AI, Hanel RA, Kirmani JF, Yahia AM, Hopkins LN. Cerebral blood flow changes associated with intracerebral hemorrhage. *Neurosurg Clin N Am.* 2002;13:355–70.
10. Qureshi AI, Wilson DA, Hanley DF, Traystman RJ. No evidence for an ischemic penumbra in massive experimental intracerebral hemorrhage. *Neurology.* 1999;52:266–72.
11. Kim-Han JS, Kopp SJ, Dugan LL, Diringer MN. Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. *Stroke J Cereb Circ.* 2006;37:2457–62.
12. Nilsson OG, Polito A, Saveland H, Ungerstedt U, Nordstrom CH. Are primary supratentorial intracerebral hemorrhages surrounded by a biochemical penumbra? A microdialysis study. *Neurosurgery.* 2006;59:521–8; discussion-8.
13. Zhang Z, Zhang Z, Lu H, Yang Q, Wu H, Wang J. Microglial polarization and inflammatory mediators after intracerebral hemorrhage. *Mol Neurobiol.* 2017;54:1874–86.
14. Gao Z, Wang J, Thies R, Rogove AD, Heppner FL, Tsirka SE. Microglial activation and intracerebral hemorrhage. *Acta Neurochir Suppl.* 2008;105:51–3.
15. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. *Physiol Rev.* 2011;91:461–553.
16. Taylor RA, Chang CF, Goods BA, et al. TGF- β 1 modulates microglial phenotype and promotes recovery after intracerebral hemorrhage. *J Clin Invest.* 2017;127:280–92.
17. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. *Lancet.* 2009;373:1632–44.
18. Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. *Neurol Res.* 2005;27:268–79.
19. Lan X, Han X, Liu X, Wang J. Inflammatory responses after intracerebral hemorrhage: from cellular function to therapeutic targets. *J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab.* 2018;271678x18805675.
20. Wang J, Dore S. Inflammation after intracerebral hemorrhage. *J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab.* 2007;27:894–908.
21. Zhou Y, Wang Y, Wang J, Anne Stetler R, Yang QW. Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation. *Prog Neurobiol.* 2014;115:25–44.
22. Beez T, Steiger HJ, Ertman N. Pharmacological targeting of secondary brain damage following ischemic or hemorrhagic stroke, traumatic brain injury, and bacterial meningitis—a systematic review and meta-analysis. *BMC Neurol.* 2017;17:209.
23. Pongvarin N, Bhoopat W, Viriyavejakul A, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. *N Engl J Med.* 1987;316:1229–33.
24. Hillered L, Persson L, Nilsson P, Ronne-Engstrom E, Enblad P. Continuous monitoring of cerebral metabolism in traumatic brain injury: a focus on cerebral microdialysis. *Curr Opin Crit Care.* 2006;12:112–8.
25. Ungerstedt U. Microdialysis—principles and applications for studies in animals and man. *J Intern Med.* 1991;230:365–73.
26. Hutchinson PJ, Jalloh I, Helmy A, et al. Consensus statement from the 2014 International Microdialysis Forum. *Intensive Care Med.* 2015;41:1517–28.
27. Hillman J, Aneman O, Anderson C, Sjogren F, Saberg C, Mellergard P. A microdialysis technique for routine measurement of macromolecules in the injured human brain. *Neurosurgery.* 2005;56:1264–8; discussion 8–70.
28. Clausen F, Marklund N, Hillered L. Acute inflammatory biomarker responses to diffuse traumatic brain injury in the rat monitored by a novel microdialysis technique. *J Neurotrauma.* 2019;36:201–11.
29. Mellergard P, Aneman O, Sjogren F, Saberg C, Hillman J. Differences in cerebral extracellular response of interleukin-1 beta, interleukin-6, and interleukin-10 after subarachnoid hemorrhage or severe head trauma in humans. *Neurosurgery.* 2011;68:12–9.
30. Mellergard P, Sjogren F, Hillman J. Release of VEGF and FGF in the extracellular space following severe subarachnoidal hemorrhage or traumatic head injury in humans. *Br J Neurosurg.* 2010;24:261–7.
31. Hillman J, Aneman O, Persson M, Andersson C, Dabrosin C, Mellergard P. Variations in the response of interleukins in neurosurgical intensive care patients monitored using intracerebral microdialysis. *J Neurosurg.* 2007;106:820–5.
32. Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. *J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab.* 2011;31:658–70.
33. Helmy A, Carpenter KL, Skepper JN, Kirkpatrick PJ, Pickard JD, Hutchinson PJ. Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery. *J Neurotrauma.* 2009;26:549–61.
34. Dyhrfort P, Shen Q, Clausen F, et al. Monitoring of protein biomarkers of inflammation in human traumatic brain injury using microdialysis and proximity extension assay technology in neurointensive care. *J Neurotrauma.* 2019;36:2872–85.
35. Dziedzic T, Bartus S, Klimkowicz A, Motyl M, Slowik A, Szczudlik A. Intracerebral hemorrhage triggers interleukin-6 and interleukin-10 release in blood. *Stroke J Cereb Circ.* 2002;33:2334–5.
36. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke. *Stroke J Cereb Circ.* 1996;27:1553–7.
37. Castillo J, Davalos A, Alvarez-Sabin J, et al. Molecular signatures of brain injury after intracerebral hemorrhage. *Neurology.* 2002;58:624–9.
38. Silva Y, Leira R, Tejada J, Lainez JM, Castillo J, Davalos A. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. *Stroke J Cereb Circ.* 2005;36:86–91.
39. Tobieson L, Rossitti S, Zsigmond P, Hillman J, Marklund N. Persistent metabolic disturbance in the perihemorrhagic zone despite a normalized cerebral blood flow following surgery for intracerebral hemorrhage. *Neurosurgery.* 2018. <https://doi.org/10.1093/neuros/nyy179>.
40. Engstrom M, Polito A, Reinstrop P, et al. Intracerebral microdialysis in severe brain trauma: the importance of catheter location. *J Neurosurg.* 2005;102:460–9.
41. Hutchinson P, O'Phelan K. International multidisciplinary consensus conference on multimodality monitoring: cerebral metabolism. *Neurocrit Care.* 2014;21(Suppl 2):S148–58.
42. Hillman J, Milos P, Yu ZQ, Sjogren F, Anderson C, Mellergard P. Intracerebral microdialysis in neurosurgical intensive care patients utilising catheters with different molecular cut-off (20 and 100 kD). *Acta Neurochir.* 2006;148:319–24; discussion 24.
43. Wheelock AM, Wheelock CE. Trials and tribulations of 'omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. *Mol BioSyst.* 2013;9:2589–96.
44. Mayne M, Ni W, Yan HJ, et al. Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage. *Stroke J Cereb Circ.* 2001;32:240–8.
45. Xi G, Hua Y, Bhasin RR, Ennis SR, Keep RF, Hoff JT. Mechanisms of edema formation after intracerebral hemorrhage: effects of extravasated red blood cells on blood flow and blood-brain barrier integrity. *Stroke J Cereb Circ.* 2001;32:2932–8.

46. Lu A, Tang Y, Ran R, Ardizzone TL, Wagner KR, Sharp FR. Brain genomics of intracerebral hemorrhage. *J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab*. 2006;26:230–52.
47. Wagner KR, Beiler S, Beiler C, et al. Delayed profound local brain hypothermia markedly reduces interleukin-1beta gene expression and vasogenic edema development in a porcine model of intracerebral hemorrhage. *Acta Neurochir Suppl*. 2006;96:177–82.
48. Engelhardt S, Patkar S, Ogunshola OO. Cell-specific blood–brain barrier regulation in health and disease: a focus on hypoxia. *Br J Pharmacol*. 2014;171:1210–30.
49. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. *J Clin Investig*. 2000;106:829–38.
50. Helmy A, Guilfoyle MR, Carpenter KL, Pickard JD, Menon DK, Hutchinson PJ. Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury. *J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab*. 2016;36:1434–48.
51. Lan X, Han X, Li Q, Yang QW, Wang J. Modulators of microglial activation and polarization after intracerebral haemorrhage. *Nat Rev Neurol*. 2017;13:420–33.
52. Liu X, Liu J, Zhao S, et al. Interleukin-4 is essential for microglia/macrophage M2 polarization and long-term recovery after cerebral ischemia. *Stroke J Cereb Circ*. 2016;47:498–504.
53. Marín-Teva JL, Cuadros MA, Martín-Oliva D, Navascués J. Microglia and neuronal cell death. *Neuron Glia Biol*. 2011;7:25–40.
54. Mracsko E, Veltkamp R. Neuroinflammation after intracerebral hemorrhage. *Front Cell Neurosci*. 2014;8:388.
55. Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. *Prog Neurobiol*. 2010;92:463–77.
56. Zhao X, Grotta J, Gonzales N, Aronowski J. Hematoma resolution as a therapeutic target: the role of microglia/macrophages. *Stroke J Cereb Circ*. 2009;40:S92–4.
57. Gordon S. Alternative activation of macrophages. *Nat Rev Immunol*. 2003;3:23–35.
58. Pelegrín P, Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. *Embo J*. 2009;28:2114–27.
59. Lopez-Castejón G, Baroja-Mazo A, Pelegrín P. Novel macrophage polarization model: from gene expression to identification of new anti-inflammatory molecules. *Cell Mol Life Sci CMLS*. 2011;68:3095–107.
60. Cavaillon JM. Pro-versus anti-inflammatory cytokines: myth or reality. *Cell Mol Biol (Noisy-le-Grand, France)*. 2001;47:695–702.
61. Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. *J Allergy Clin Immunol*. 2010;125:S53–72.
62. Hutchinson PJ, O'Connell MT, Rothwell NJ, et al. Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. *J Neurotrauma*. 2007;24:1545–57.
63. Shiozaki T, Hayakata T, Tasaki O, et al. Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. *Shock*. 2005;23:406–10.
64. Ungerstedt U, Rostami E. Microdialysis in neurointensive care. *Curr Pharm Des*. 2004;10:2145–52.
65. Fahlstrom A, Tobieson L, Redebrandt HN, et al. Differences in neurosurgical treatment of intracerebral haemorrhage: a nation-wide observational study of 578 consecutive patients. *Acta Neurochir*. 2019.